Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 451-458

  Simó, Marta ^a   Velasco, Roser ^a   Graus, Francesc ^b   Verger, Eugenia ^b   Gil, Miguel ^a   Pineda, Estela ^b   Blasco, Jaume ^a   Bruna, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiepileptic drugs; Glioblastoma; Hematological toxicity; Survival; Temozolomide; Thrombocytopenia

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; PHENYTOIN; TEMOZOLOMIDE; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; BLOOD TOXICITY; CANCER PATIENT; CANCER PROGNOSIS; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; EPILEPSY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84864041314     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0836-1     Document Type: Review

References (47)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-299
2. Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
3. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47-52 (Pubitemid 46543488)
4. Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688-690 (Pubitemid 46667817)
5. Vecht CJ, Wilms EB (2010) Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 10:663-669
6. Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421-430 (Pubitemid 46551867)
7. Vecht CJ, Van Breemen M (2006) Optimizing therapy of seizures in patients with brain tumors. Neurology 67(12 suppl 4):S10-S13 (Pubitemid 44967990)
8. Badyal DK, Dadhich AP (2001) Cytochrome P450 and drug interactions. Indian J Pharmacol 33:248-259 (Pubitemid 32842517)
9. Patsalos PN, Fröscher W, Pisani F, Van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365-385 (Pubitemid 34297175)
10. Anderson GD (2004) Pharmacogenetics and enzyme induction/ inhibition properties of antiepileptic drugs. Neurology 63(suppl 4):S3-S8 (Pubitemid 39532357)
11. Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2: 404-409 (Pubitemid 36793932)
12. Vecht CJ, Wagner GL, Wilms EB (2003) Treating seizures in patients with brain tumors: drug interactions between antiepi-leptic and chemotherapeutic agents. Semin Oncol 30(6 suppl 19):49-52 (Pubitemid 38199165)
13. Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR (2003) Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 97(suppl 9):2374-2380 (Pubitemid 36444048)
14. Villikka K, Kivisto KT, Mäenpää H, Joensuu H, Neuvonen PJ (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66:589-593 (Pubitemid 30014085)
15. Jaeckle KA, Ballman K, Furth A, Buckner JC (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207-1213
16. Oberdornfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenber-ger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255-260 (Pubitemid 40867409)
17. Weller M, Gorlia T, Cairncross JC et al (2011) Prolonged sur-vival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156-1164
18. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M (2001) Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 12:217-219 (Pubitemid 32223871)
19. Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585-2597 (Pubitemid 30482092)
20. Blackburn SC, Oliart AD, García Rodŕguez LA, Pérez Gutthann S (1998) Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18:1277-1283 (Pubitemid 28533881)
21. Nasreddine W, Beydoun A (2008) Valproate-induced thrombo-cytopenia: a prospective monotherapy study. Epilepsia 49:438-445 (Pubitemid 351294539)
22. Kimland E, Höjeberg B, Von Euler M (2004) Levetiracetam-induced thrombocytopenia. Epilepsia 45:877-878 (Pubitemid 38890992)
23. Mesche A, Runge U, Sabolek M (2008) Thrombocytopenia during levetiracetam therapy. Epilepsy Res 80:91-92
24. Gallerani M, Mari E, Boaria B, Carletti R, Marra A, Cavallo M (2009) Pancytopenia associated with levetiracetam treatment. Clin Drug Investig 29:747-751
25. Elouni B, Ben Salem C, Biour M (2009) Levetiracetam-induced pancytopenia. Ann Pharmacother 43:985
26. Oghlakian R, Nock C, Koubeissi M (2010) A case of leveti-racetam-induced thrombocytopenia. Epileptic Disord 12:335-337
27. Sahaya K, Goyal MK, Sarwal A, Singh NN (2010) Levetirace-tam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 51:2492-2495
28. Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55 (Pubitemid 28027566)
29. Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569 (Pubitemid 46630635)
30. Chang SM, Parney IF, Huang W et al (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293: 557-564 (Pubitemid 40171237)
31. Macdonald D, Cascino T, Schold SJ, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
32. Maschio M, Albani F, Jandolo B et al (2008) Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol 90:217-221
33. Van Breemen M, Rijsman RM, Taphoorn MJB, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519-1526
34. Maschio M, Dinapoli L, Vidiri A et al (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28:60
35. Maschio M, Dinapoli L, Saveriano F et al (2009) Efficacy and tolerability of zonisamide as add-on in brain tumor-related epi-lepsy: preliminary report. Acta Neurol Scand 120:210-212
36. Merrell RT, Anderson SK, Meyer FB, Lachance DH (2010) Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg 113:1176-1181
37. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76
38. Armstrong TS, Cao Y, Scheurer ME et al (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 11:825-832
39. Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107:207-212
40. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bev-acizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
41. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radio-therapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
42. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
43. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737-744 (Pubitemid 38890970)
44. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912-1922 (Pubitemid 43056974)
45. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 12:328-340
46. Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT (2011) Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med 89:303-315
47. Bobustuc GC, Baker CH, Limaye A et al (2010) Levetiracetam enhances p53-mediates MGMT inhibition and sensitizes glio-blastoma cell to temozolomide. Neuro Oncol 12:917-927